Antithrombin Market Size by Source, Dosage Type, Application, Region – Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032
Overview
Antithrombin Market size is expected to reach nearly US$ 758.69 Mn. by 2032 with the CAGR of 4.82% during the forecast period.
Antithrombin Market Overview:
Antithrombin (AT) is a small protein molecule that aids in the inactivation of coagulation system enzymes. It's often used during surgical procedures in patients with low antithrombic levels, and it serves as a natural blood thinner. Antithrombin is a serine protease inhibitor with a structure similar to alpha 1-antichymotrypsin, alpha 2-antiplasmin, and heparin cofactor II.
To know about the Research Methodology :- Request Free Sample Report
Antithrombin Market Dynamics:
Rising prevalence of surgical procedures and advances in the technology are the major drivers for the market growth.
Antithrombin is being used to treat many medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO). Increasing incidences of these conditions are creating potential growth opportunities for the Antithrombin market. According to the Centres for Disease Control and Prevention (CDC), venous thromboembolism affects about 900,000 people in the United States each year. Furthermore, hereditary thrombophilia puts 5 to 8% of the population in the United States at risk of thrombosis due to one of many genetic risk factors. Clopidogrel, a currently approved antiplatelet agent, meets some of these requirements and has contributed significantly to the antithrombotic market's recent development.
Furthermore, the use of antithrombin and heparin may be more effective in the treatment of patients with antithrombin disorders. Antithrombin benefits and applications contribute to the market's development. The rising number of surgeries conducted worldwide and the risk of excessive bleeding during these procedures is expected to boost the market growth. Along with this, Therapeutic drug advances are also expected to drive market growth. Fitusiran (ALN-AT3), a subcutaneously administered investigational RNAi therapeutic targeting antithrombin, was developed by Alnylam Pharmaceuticals, Inc. (AT). This therapeutic, which can be used to treat hemophilia and rare bleeding disorders (RBDs), is currently in a late-stage clinical trial (Phase 2-phase 3).
However, the high cost for antithrombin procedure and lack of adequate technological infrastructure in underdeveloped economies are expected to restrain the market growth. In addition to this, increased use of biologics and availability of alternative options may also impact negatively on the market growth.
The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Antithrombin Market Segment Analysis:
The global Antithrombin market is segmented on the basis of Application, Source and Dosage form.
Based on the Application, the Therapeutics segment is anticipated to hold the largest market share over the forecast period. It accounted for a market share of xx% in the year 2025. It has widespread application in the therapeutics area. Antithrombin can be used to treat conditions such as heart surgery and genetic disorders such as Antithrombin Deficiency. According to data released by the American Society of Haematology, 900,000 people in the United States produce blood clots per year, resulting in nearly 100,000 deaths. According to the National Organization for Rare Disorders, Type I antithrombin deficiency affects one in every 3000 to 5000 individuals in the United States.
Antithrombin is being used both therapeutically and diagnostically as the incidence of blood clotting disorders rises.
Based on Dosage Form, the Lyophilized segment held the largest market share in 2025. The lyophilized dosage type is commonly available and has a long expiration date. It also contributes to the growth of this segment by maximizing the integrity and ease of processing a liquid.
Antithrombin Market Regional Insights:
North America is anticipated to account for dominant market share during forecast period.
The U.S. accounted for US$ xx Million in the year 2025. This is due to a rise in antithrombin awareness, acceptance, and adoption in this region's countries. The popularity of antithrombin is growing in this area due to an increase in the number of people with coagulation disorders.
Asia Pacific is expected to witness lucrative growth during forecast years.
Asia Pacific Antithrombin Market is expected to expand at the fastest pace. The Antithrombin Market was worth US$ xx million in the Asia Pacific alone in 2025. One of the main reasons for this increase is that developing countries like India and China are introducing new treatment procedures and techniques to combat different diseases.
The report also helps in understanding Global Antithrombin Market dynamics, structure by analyzing the market segments and project the Global Antithrombin Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antithrombin Market make the report investor’s guide.
Antithrombin Market, Key developments:
Three major corporations dominated the global Antithrombin Market: SCL Behring, Grifols, and Shire. These three firms accounted for the largest market share among others in 2025. They have the most widely used anticoagulants dependent on human antithrombin. Apart from this, they have a wide distribution network that allows them to capture the largest market share.
Antithrombin Market Scope: Inquire before buying
| Global Antithrombin Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 545.7 USD Mn. |
| Forecast Period 2026-2032 CAGR: | 4.82% | Market Size in 2032: | 758.69 USD Mn. |
| Segments Covered: | by Source | Human Recombinant Goat milk Others |
|
| by Dosage Type | Lyophilized Liquid |
||
| by Application | Therapeutics Diagnostics Research Other |
||
| by End User | Hospitals & Clinics Pharmaceutical & Biotechnology Industry Research Institutes |
||
Antithrombin Market, By Region:
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Antithrombin Market Key Players are:
1. rEVO Biologics, Inc.
2. Grifols
3. CSL Limited
4. Kedrion S.p.A
5. Octapharma AG
6. Dem ilac Inc.
7. Lee Bisolutions
8. Diapharma
9. Scripps Laboratories, Inc.
10.LFB USA
11.Shire Plc.
12.Takeda Pharmaceutical Company Limited
13.Koliber Biosciences
14.Siemens Healthcare Private Limited
15.Aniara Diagnostica
16.Sysmex Corporation
17.Trinity Biotech PLC
Frequently Asked questions
1. What is the market size of the Global Antithrombin Market in 2025?
Ans. The market size Global Antithrombin Market in 2025 was US$ 545.70 Million.
2. What are the different segments of the Global Antithrombin Market ?
Ans. The Global Antithrombin Market is divided into Source, Dosage Type, Application and End User .
3. What is the study period of this market?
Ans. The Global Antithrombin Market will be studied from 2025 to 2032.
4. Which region is expected to hold the highest Global Antithrombin Market share?
Ans. The Asia Pacific dominates the market share in the market.
5. What is the Forecast Period of Global Antithrombin Market ?
Ans. The Forecast Period of the market is 2026-2032 in the market.